Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Up 13.6% in January

Cellebrite DI Ltd. (NASDAQ:CLBT) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, a growth of 13.6% from the December 31st total of 1,030,000 shares. Approximately 1.4% of the shares of the stock are short sold. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is currently 0.9 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on CLBT shares. JPMorgan Chase & Co. raised their target price on Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Craig Hallum raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC raised their price target on shares of Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI presently has an average rating of “Buy” and an average price target of $21.57.

Cellebrite DI Stock Up 1.7 %

CLBT traded up $0.41 during trading on Monday, reaching $24.45. The company’s stock had a trading volume of 807,412 shares, compared to its average volume of 1,501,623. The firm has a fifty day simple moving average of $21.77 and a two-hundred day simple moving average of $18.46. Cellebrite DI has a 1 year low of $8.91 and a 1 year high of $24.62. The company has a market cap of $5.04 billion, a price-to-earnings ratio of -15.77, a PEG ratio of 3.55 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.09 EPS. As a group, equities analysts forecast that Cellebrite DI will post 0.32 EPS for the current fiscal year.

Institutional Trading of Cellebrite DI

Several institutional investors have recently made changes to their positions in the company. Quarry LP acquired a new stake in Cellebrite DI in the 3rd quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. increased its holdings in Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC increased its holdings in Cellebrite DI by 1,583.8% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after purchasing an additional 4,118 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in Cellebrite DI in the 4th quarter valued at approximately $100,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.